FDA approvals arrive for ClearPoint Neuro and MicroPort Navibot. 

There are plenty of radiologists serving Medicare patients in the U.S., but the headcounts are unevenly distributed, and widely so.   

A medical AI startup in Omaha, Neb., has received the FDA’s blessing to market software for diagnosing prostate cancer on MRI scans.

MRI technologists serving patients who have difficulty understanding English may need to budget additional scanner time—especially when image quality largely depends on patients’ compliance with breathing instructions.

The FDA’s Center for Devices and Radiological Health (CDRH) has updated the status of two previously disaccredited mammography operations, rehabilitating the reputation of one while showing the other in limbo.

The presence of any or all of four factors can help ensure appropriate CT utilization in emergency settings: established diagnostic pathways, alternative test availability, involvement of specialists and feedback from referrers.

The commoditization of health data raises questions about who is owed what, and in what proportion, when artificial intelligence renders the data clinically useful and thereby financially profitable.

Point-of-care MRI is a worthwhile diagnostic option for emergency departments and ICUs concerned about wait or transport times to access fixed MRI for patients with neuroimaging needs.